Stockscreener 앱 받기
11.21
0.45%
0.05
시간 외 거래:
11.25
0.04
+0.36%
전일 마감가:
$11.16
열려 있는:
$11
하루 거래량:
3.56M
Relative Volume:
0.76
시가총액:
$1.57B
수익:
$67.67M
순이익/손실:
$-412.69M
주가수익비율:
-2.9295
EPS:
-3.8266
순현금흐름:
$-395.87M
1주 성능:
-1.84%
1개월 성능:
-9.08%
6개월 성능:
-29.36%
1년 성능:
-56.70%
1일 변동 폭
$10.58
$11.24
1주일 범위
$10.58
$11.99
52주 변동 폭
$7.95
$26.35
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.21 | 1.57B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-06 | 개시 | Barclays | Underweight |
| 2026-07-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2026-03-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-10-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history - Yahoo Finance UK
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics - Yahoo Finance
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research
Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) options chain - Yahoo Finance Australia
Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock - Endpoints News
Intellia Therapeutics names Jing Marantz as EVP and CMO - The Pharma Letter
Intellia Therapeutics names Jing Marantz as chief medical officer - Investing.com
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Intellia Therapeutics
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I - TradingView
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Zacks Investment Research
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Yahoo Finance
To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale. - Stock Titan
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target - marketscreener.com
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target - Yahoo Finance
Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. - Stock Titan
Intellia Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Eight new employees got Intellia stock awards, with vesting scheduled over three years. - Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now? - Simply Wall Street
Tangible book value per share of Intellia Therapeutics, Inc. – HAN:38I - TradingView
Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance
No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies - Morningstar
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Barchart.com
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA) - Seeking Alpha
Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Yahoo Finance
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Canada
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intellia Therapeutics Inc 주식 (NTLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ELIANA CLARK | Officer |
Oct 05 '26 |
Proposed Sale |
12.75 |
57,750 |
736,312 |
0 |
| LEONARD JOHN M | President and CEO |
Aug 21 '26 |
Sale |
13.00 |
2,785 |
36,205 |
1,147,064 |
| LEONARD JOHN M | Officer |
Aug 20 '26 |
Proposed Sale |
12.95 |
22,675 |
293,641 |
0 |
| LEONARD JOHN M | President and CEO |
Aug 20 '26 |
Sale |
12.60 |
19,890 |
250,614 |
1,149,849 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 22 '26 |
Sale |
11.25 |
8,111 |
91,249 |
148,175 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 02 '26 |
Sale |
18.00 |
4,677 |
84,186 |
156,286 |
| EDWARD DULAC | Officer |
Jul 02 '26 |
Proposed Sale |
17.24 |
4,677 |
80,631 |
0 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 01 '26 |
Sale |
16.78 |
2,641 |
44,316 |
66,886 |
| BASTA JAMES | EVP, General Counsel |
Mar 02 '26 |
Sale |
13.78 |
1,211 |
16,688 |
156,794 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
2.11%
2.03%
자본화:
|
볼륨(24시간):